Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. TSLA
2. SPY
3. META
4. INTC
5. HOOD
6. STZ
7. FUTU
8. AMZN
9. MSFT
10. SPCX

Go back to Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
(NASDAQ: KPRX) Delayed: 2.63 -0.03 (1.13%)
Previous Close $2.66    52 Week High $ 
Open $2.68    52 Week Low $ 
Day High $2.74    P/E N/A 
Day Low $2.62    EPS $ 
Volume 8,964